GWPH News and Press, GW Pharmaceuticals Plc From 09/28/19

Will this week go down in cannabis history? It's very possible, thanks to the passing of the SAFE Banking Act in the House of Representatives. This is a potential game-changer for the cannabis retail segment, if it passes in the Senate. Meanwhile, there were also developments with marijuana st...

The confusing case of Zynerba ( ZYNE ) continues to show that the medical cannabis space is basically completely unpredictable. The stock is down about a third since announcing what it called positive results for its Zygel transdermal cannabidiol [CBD] treatment for various forms of childhoo...

GW Pharmaceuticals (NASDAQ: GWPH) has been granted approval by the European Commission to sell its star drug Epidyolex in the European Union (EU). The company announced that the Commission, the EU's pharmaceutical regulator, has authorized Epidyolex for aiding in the treatment of seizures in...

CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that ...

Daniel Goldmeier of Goldmeier Investments assisted in writing this article. Too Much Risk Too Soon Israel's Teva Pharmaceutical Industries Ltd. ( TEVA ) share price sells a notch above its 19 years low. Yet, I do not recommend retail investors buy this stock now. The company has no maj...

September 24, 2019 Palm Beach, FL – September 24, 2019 – As cannabis legalization spreads, another drug may soon follow in its footsteps — psilocybin mushrooms.  In fact, analysts argue mushrooms may hold untapped medical properties that could be used to ...

Major benchmarks moved mostly sideways Monday, as weak economic data from Germany failed to discourage U.S. investors. The  Dow Jones Industrial Average (DJINDICES: ^DJI)  and the  S&P 500 (SNPINDEX: ^GSPC)  started out in the red but recovered during the session to c...

GWPH stock is witnessing solid gains in early session on Monday after GW Pharmaceuticals (NASDAQ:GWPH) announced that the European regulators approved the company’s CBD oil in two seizure disorders. Impressive Development The cannabis industry has been reeling from a supply slowd...

Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cann...

There's little doubt that the U.S. is going to be the most lucrative legal cannabis market, once it's fully up and running, and assuming pot is legalized federally. And while the No. 2 spot has typically belonged to Canada, it may not end up that way. While Canada certainly has a head start, hav...